Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Sells $18,947.25 in Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 945 shares of Pacira BioSciences stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $20.05, for a total transaction of $18,947.25. Following the completion of the sale, the insider now owns 94,307 shares of the company’s stock, valued at $1,890,855.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jonathan Slonin also recently made the following trade(s):

• On Tuesday, July 2nd, Jonathan Slonin sold 2,836 shares of Pacira BioSciences stock. The shares were sold at an average price of $28.25, for a total transaction of $80,117.00.
• On Tuesday, June 11th, Jonathan Slonin sold 5,012 shares of Pacira BioSciences stock. The shares were sold at an average price of $28.57, for a total transaction of $143,192.84.

Pacira BioSciences Trading Up 2.5 %

PCRX opened at $21.26 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.82 and a quick ratio of 4.78. Pacira BioSciences, Inc. has a fifty-two week low of $19.34 and a fifty-two week high of $40.16. The firm has a market capitalization of $980.72 million, a PE ratio of 14.87 and a beta of 0.88. The company’s 50-day moving average is $25.03 and its 200 day moving average is $27.80.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The company had revenue of $167.12 million for the quarter, compared to the consensus estimate of $165.43 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. As a group, research analysts predict that Pacira BioSciences, Inc. will post 2.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on PCRX. HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Pacira BioSciences in a research report on Tuesday, July 2nd. Raymond James lowered their price objective on shares of Pacira BioSciences from $41.00 to $37.00 and set an “outperform” rating for the company in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Royal Bank of Canada lowered their price objective on shares of Pacira BioSciences from $42.00 to $37.00 and set an “outperform” rating for the company in a research report on Wednesday, July 31st. Finally, Piper Sandler restated an “overweight” rating and set a $42.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, July 3rd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $41.44.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PCRX. ICA Group Wealth Management LLC purchased a new stake in shares of Pacira BioSciences during the 4th quarter valued at $30,000. GAMMA Investing LLC raised its position in Pacira BioSciences by 229.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after purchasing an additional 932 shares during the period. Park Place Capital Corp purchased a new position in Pacira BioSciences in the 2nd quarter worth $46,000. Innealta Capital LLC purchased a new position in Pacira BioSciences in the 2nd quarter worth $50,000. Finally, nVerses Capital LLC raised its position in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares during the period. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.